All News
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
MedPage Today
Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.
Read Article
What to do about pre-clinical RA?
RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, and in particular, what to do regarding pre-clinical RA.
Read Article
The Origin Story: Women in Rheumatology--The XX Factor
When asked to run a campaign to highlight the achievements and challenges of women in rheumatology, I was ecstatic because we have has so many heroines who have contributed to our field.
https://t.co/ucQIPjQ8Tu https://t.co/g81EtAwYYL
Links:
Dr. John Cush RheumNow ( View Tweet)
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor.
Sign up to attend our Tuesday Night Rheumatology series.
@uptoTate @KDAO2011
https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN
Links:
Dr. John Cush RheumNow ( View Tweet)
Among 182 adult #RA pts - half (50%) had Depression and 25% had anxiety. Patients with depression or anxiety had higher HAQ and DAS28 scores. Depression was more prevalent in females, housewives, & low education. Anxiety more in blue-collar workers https://t.co/C9Foulu29l https://t.co/tcCaV85kU0
Links:
Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology.
Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations.
https://t.co/OlP0pupkMV https://t.co/pZQMASafcG
Links:
Dr. John Cush RheumNow ( View Tweet)
Variability in rheumatologist steroid prescribing - using data on ~500k RA pts and 6,875 rheumatologists. Those LESS likely to prescribe alot of steroids were: women, solo practitioners, in practice ≥10 years, seeing greater#s of RA pts/year https://t.co/ELk0avorOe
Links:
Dr. John Cush RheumNow ( View Tweet)
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/dsbjPhuYzf https://t.co/1Zmyqjuaxj
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E
Links:
Dr. John Cush RheumNow ( View Tweet)
Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM
Links:
Dr. John Cush RheumNow ( View Tweet)
30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/T7CRLzhOMD https://t.co/nYPEw72zOJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed.
https://t.co/XKjuxLWAKH https://t.co/M7ri9AL2wH
Links:
Dr. John Cush RheumNow ( View Tweet)
What to do about pre-clinical RA?
Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056
Links:
Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW
Links:
Dr. John Cush RheumNow ( View Tweet)
Biosimilars are coming!
Multiple adalimumab biosimilars this year
- will we see a dramatic price difference?
@RheumNow #RNL2023 https://t.co/8vdtXtEGOO
Robert B Chao, MD doctorRBC ( View Tweet)
Will be begin using sputum instead of blood serologies to detect RA?
- sputum seropositive CCP may be associated with development of clinical RA
- 4 fold higher risk if (induced) sputum CCP+
@RheumNow #RNL2023 https://t.co/Z85GDwIyl8
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
Sputum antibody predicts future development of RA
Hazard ratio 4.2 if any sputum antibody positive (CCP IgG/IgA, RF IgM and IgA)
Strongest association with CCP IgA
Supports pre-RA as mucosal disease
@RheumNow https://t.co/Js4JPZiLDB
Eric Dein ericdeinmd ( View Tweet)
Smoking *may* only ⬆️ risk of #RA if shared epitope present AND double positive
By @Janetbirdope #RNL2023 https://t.co/TG1hseVCsD
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Could MTX every other week dosing be an option in patients with stable disease..?
#RNL2023 https://t.co/EZRdQnuXjy
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
